<DOC>
	<DOCNO>NCT01768663</DOCNO>
	<brief_summary>The purpose study examine drug-drug interaction effect ciprofloxacin , itraconazole , rifampin pharmacokinetics lumacaftor combination ivacaftor well evaluate potential effect lumacaftor combination ivacaftor lung function .</brief_summary>
	<brief_title>A Phase 1 Study Examine Drug-Drug Interaction Ciprofloxacin , Itraconazole , Rifampin Combination Lumacaftor With Ivacaftor Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Male female subject must age 18 55 year , inclusive Body mass index ( BMI ) 18 31 kg/m2 , inclusive , total body weight &gt; 50 kg . History illness , opinion investigator , might confound result study pose additional risk administer study drug ( ) subject . This may include , limited , history relevant drug food allergy ; history cardiovascular central nervous system disease ; history presence clinically significant pathology ; history mental disease . History febrile illness within 5 day first dose . History Gilbert 's syndrome Abnormal renal function define screen Blood donation approximately 1 pint ( 500 mL ) within 56 day study drug administration Treatment investigational drug within 30 day 5 halflives ( determined local requirement , whichever long ) precede first dose study drug Known hypersensitivity prior adverse reaction ciprofloxacin , member quinolone class antimicrobial agent ( Cohort 1 ) ; itraconazole , azoles ( Cohort 2 ) ; rifampin , rifamycins ( Cohort 3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>